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Abstract 
The diagnosis of human T-cell leukemia virus type-1 (HTLV-1) infection has been widely 
examined by serologics. In the first screening tests, serological false negative and 
positive samples have been reduced thanks to advances in assay techniques that apply 
new emission agents and sensors. On the other hand, western blot (WB) remains 
problematic. For example, WB analysis yields many samples equivalent to antibody 
positive ones. To reduce the need for WB, an alternative testing strategy is required to 
detect HTLV-1 infection. Polymerase chain reaction (PCR) for the HTLV-1 provirus has 
recently been recommended for a final diagnosis of infection. However, although PCR is 
thought to be one element, the validation of detection performance for HTLV-1 infection 
between serological and molecular testing is not always clear. Thus, this study aimed to 
evaluate the accuracy and test the validity of an improved methodology for serological 
detection of HTLV-infection, as well as that of PCR. In conclusion, the high values of 
kappa-statistics are expected to deliver high quality in chemiluminescent enzyme 
immunoassay (or chemiluminescent immunoassay), while the problems with WB assays 
remain to be elucidated. As an alternative to WB, a combination of real-time qPCR and 






  Recently, the diagnosis of human T-cell leukemia virus type-1 (HTLV-1) infection has 2 
been widely examined by serological tests1-7). Screening of serum by particle 3 
agglutinations (PA) and chemi-luminescent immune assays (Chemiluminescent Enzyme 4 
Immunoassay: CLEIA and chemiluminescent immunoassay: CLIA) and confirmation by 5 
western blot (WB) is a common testing strategy8,9). However, when this strategy is 6 
applied to low infection prevalence populations, false positive samples may increase 7 
markedly, because the first screening tests are usually highly sensitive and low specific. 8 
Furthermore, WB as a confirmatory test is known to yield many indeterminate results. In 9 
the first screening tests, serological false negative and positive samples have been 10 
reduced thanks to advances in assay techniques applying new emission agents and 11 
sensors. On the other hand, WB remains problematic. For example, WB analysis yields 12 
many samples equivalent to antibody positive ones. To reduce the need for WB, an 13 
alternative testing strategy is required to detect HTLV-1 infection.  14 
Polymerase chain reaction (PCR) for the HTLV-1 provirus has recently been 15 
recommended for a final diagnosis of infection10). However, although PCR is thought to 16 
be one element, the validation of detection performance for HTLV-1 infection between 17 
serological and molecular testing is not always clear. Thus, this study aimed to evaluate 18 
the accuracy and test the validity of an improved methodology for serological detection 19 
of HTLV-infection, as well as that of PCR.   20 
 21 
Material and Methods 22 
Materials 23 




were used. During this period, 9,718 samples were tested for screening. 105 samples 25 
excluding double negative in PA and CLEIA samples were used as the secondary 26 
samples, and were examined for infection by 4 methods as described below. Meanwhile, 27 
using 25 practical blood samples collected from hospitalized patients in complete 28 
remission from adult T-cell leukemia (ATL), the role of PCR in serological detection of 29 
HTLV-1 infection was investigated.    30 
Next, we examined low titer samples or sero-negative converted samples selected from 31 




 Serological detection of HTLV-1 infection was done using commercially available 36 
assay kits according to the manufacturer’s instructions, with Serodia-HTLV-Ⅰ (PA; 37 
Fuji-Rebio, Tokyo), Lumipulse-HTLV-Ⅰ (CLEIA; Fuji-Rebio, Tokyo, Japan), 38 
Architect-HTLV (CLIA; Abbott, Illinois, USA) and problot-HTLV-Ⅰ (WB; Fuji-Rebio, Tokyo, 39 
Japan). The positivity of WB analysis was decided according to the WHO criteria9). 40 
 41 
HTLV-1 proviral load (PVL): 42 
After separation of peripheral blood mononuclear cells (PBMC) in the Conray manner, 43 
genomic DNA was extracted using Qiagen kits (Qiagen, Crawley, UK. Quantitative PCR 44 
(qPCR) and quantitative nested PCR (nPCR) detection for HTLV-1 were performed as 45 
described previously11-13). Briefly, primers were set in the pX region, and the density of 46 




represented as a percentage. The detection density level was in a linear range of ~ 48 
0.5% and the lowest sensitivity was 0.1%. Furthermore, when presenting 0.1% or less, 49 
we conducted nPCR 14)and sub-classified these samples into two types of qPCR (-) and 50 
nPCR (+), and both were negative in un-infected cases.  51 
  52 
Statistics: 53 
 To evaluate the test and diagnostic performance for the qualitative detection of 54 
anti-HTLV-1, Cohen’s kappa-statistics were used. This is a more robust measure than a 55 
simple % agreement calculation. 56 
 57 
Results 58 
1. Various results with the 4 methods 59 
The positive rates by PA, CLEIA, CLIA and WB were significantly different between 60 
the former 3 methods and WB (Table 1) using pregnant blood samples. The cause of 61 
the low positive rate in WB was likely high indeterminates (14.3%). The band patterns of 62 
WB and serological and molecular status for HTLV-1 positivity are compared in Table 2. 63 
The 15 indeterminate samples consisted of 6 with no only gp46 band pattern (group A) 64 
and 9 with no gp46 and gag band (p53, p24 or p19) pattern (group B). Samples of 65 
Group A were seropositive in all but case no 21. In addition, All 3 samples (case no. of 66 
62, 60 and 100) available for molecular testing showed either a qPCR or nPCR positive 67 
reaction (Figure 1). When no amplicon was observed, the sample was re-evaluated 68 
using an increased dose of template (60ng). The amplicon curve in case 62 of Figure 1A 69 
emerged as a consequence of an increased template dose.  These findings indicate 70 




HTLV-1 provirus-integrated cells (Table 2). Thus, the condition of gp46 positivity in the 72 
WHO criteria may not be ideal. 73 
 The value of kappa-statistics concerning the validation of test performance in a 74 
combination of the two methods is summarized in Table 3. The two chemi-luminescent 75 
immune assays (CLEIA and CLIA) kits were evaluated to be excellent.    76 
 77 
2. The role of PCR in the serological diagnostic strategy of HTLV-1 infection 78 
About half the cases with sero-indeterminate WB patterns had negative or low titers in 79 
other assays. Accordingly, we examined whether the HTLV-1 provirus could be detected 80 
in low titer samples or sero-negative converted samples selected from 350 ATL patients 81 
who underwent bone marrow transplantation (BMT) and/or chemotherapy. As shown in 82 
Table 4, PVL was 0 to 0.5% in 25 of the 350 samples, consisting of 14 sero and 83 
molecular positive samples (group Ⅰ ), 7 negative qPCR samples with or without 84 
sero-positivity (group Ⅱ), and 4 sero-negative and qPCR(-) ･nPCR(+) or (-) samples 85 
(group Ⅲ).  This means that serological detection of HTLV-1 infection is better than 86 
qPCR for blood samples with a PVL of less than around 0.4%. However, if the detection 87 
sensitivity of qPCR was supplemented with nPCR, such molecular methods gave high 88 
detection rates. No sample was nPCR(-) and sero-positive. The value of 89 
kappa-statistics in the combination of qPCR and CLEIA was 0.545 and the combination 90 
of qPCR or nPCR and CLEIA was 0.744, respectively. These findings indicate we 91 
should use qPCR or nPCR and CLEIA when we test unnatural samples collected in the 92 
complete remission state after BMT and/or chemotherapy in patients with ATL. The 93 




to the detection sensitivity.  95 
 96 
Discussion 97 
Since the discovery that HTLV-1 is causative for ATL as well as HAM/TSP15,16）, about 98 
30 years have passed. However, the number of HTLV-1 carriers and annual morbidity 99 
number of ATL patients are about 1 million and about 1,000 respectively in Japan17）. 100 
Furthermore, there has been little advance in the treatment for ATL. If people are not 101 
infected with HTLV-1, no ATL develops, indicating that prevention of HTLV-1 102 
transmission is important. The natural  transmission route is known mainly to be 103 
mother to child via breast-feeding18-21 ） . The preventive effect of refraining from 104 
breast-milk has been demonstrated through the ATL Prevention Program in Nagasaki 105 
(APP), which started in 1986 18,22）. On the other hand, a nationwide prevention program 106 
similar to APP only started in Japan from 2011, including non-endemic areas for HTLV-1. 107 
The low prevalence of infection leads to a greater frequency of indeterminate or false 108 
positive results. In general, PA and CLEIA(or CLIA) methods are applied as the 109 
screening test. If HTLV-1 is positive, the result is confirmed by WB, as a confirmatory 110 
test. So the final indeterminate judgment may be undesirable for mental health of the 111 
mother. In fact, this strategy yields a high rate of inconclusive or equivalent results. 112 
Accordingly, it is now controversial as to whether or not real-time qPCR can be 113 
substituted for WB.  114 
The present study revealed that although the positive rates of PA, CLEIA and CLIA 115 
were equally high, the values of kappa-statistics gave a more robust evaluation in terms 116 




WB was the worst performer; no validity as a confirmatory test was found. The reason 118 
for this appears to result be presence of many sero-indeterminates (14.3%) in endemic 119 
erea(Nagasaki). Additionally, the present study indicated that 60 to 70% of WB 120 
indeterminates were probably positive, in particular in cases with no gp46 band. Taken 121 
together, the CLEIA (and/or CLIA) is probably suitable for the first screening, but there 122 
seems to be no appropriate serological test as a confirmatory test.  123 
Moreover, when serological assays yield discrepant results, no one knows which 124 
result is correct. From biological and confirmatory points of view, the genetic approach 125 
is promising and attractive. Thus, we compared test and diagnostic performance of 126 
PCR and serological assays. Although the benefits of real-time qPCR are well 127 
understood, as summarized schematically in Figure 2, the detection limit of 0.01% is a 128 
disadvantage of this technology. However, since a combination with nPCR became 129 
sensitive at 0.001%, nPCR(-) may be thought of as un-infected. Currently, the 130 
pathological significance in such a very low number of infected cells remains to be 131 
elucidated.  In general, the limit of detection of qPCR is thought to be 0.01 to 132 
0.5%13,23-27）, the same as with our method. If we convert 0.01% of PVL into total 133 
infected cells per body, a total of 3 x 10-4~-5 infected cells exist within the whole body, 134 
indicating that such an infected cell burden seems to be natural in the production of 135 
anti-HTLV-1 antibodies. Since even some samples with qPCR(-) and nPCR(+) were 136 
positive for the antibody, real-time qPCR may yield seropositive individuals carrying a 137 
small number of infected cells detected by only nPCR. This suggests that a 138 
combination of qPCR and nPCR is a better algorithm as a confirmatory test.  139 
In conclusion, the high values of kappa-statistics are expected to deliver high 140 




elucidated. As an alternative to WB, a combination of real-time qPCR and nested 142 
PCR is proposed as a suitable confirmatory test.  143 
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Figure Legends 242 
Figure1. 243 
Amplicon curve in Real-time qPCR in 3 samples with indeterminate WB pattern.  244 
(A)  The amplicon curve incompletely elevated out of the dynamic range using 100 ng 245 
templates. 246 
(B)  Western blot pattern of 3 sampled and that were not observed gp 46 band.  247 
PC* means weak positive control. 248 
In order to determine sero-positive, both gp46 and one or more gag band(p53, p24 or 249 
p19) were positive.   250 
(C)  The results of triplicate nested PCR in case no. 60 were showed 3 images in left panel. 251 
PCR was two times positive amplification reaction detecting agarose gel analysis.  252 
PC means positive control and NC means negative control. PC have 2 different 253 
concentrations 30 pg and 3 pg. 254 
 255 
Figure 2.   256 
The relationship between the HTLV-1 molecular proviral detection status by    PCR 257 
methodology and the HTLV-1 sero-positive status measured with the                 258 
CLEIA  method.  259 
 260 
Table 1 .  261 
The HTLV-1 serological results of 105 pregnant sera by each method. 262 
The positive rate was significantly lower in WB compared to other 3 methods (<.05) with 263 





Table 2. 266 
Comparison of results between  3sets of  serological data for the CLEIA, CLIA and PA) 267 
and 19 cases showing 4 negative  and 15 indeterminate  WB.  The cut of value for CLEIA 268 
and CLIA is 1.0. 269 
qPCR and nested PCR gave a positive amplicon  in all cases tested. 270 
 271 
Table 3 .  272 
The proportional agreement and kappa-statistic between the two methods. 273 
The values of kappa-statistics were evaluated to be poor in less than 0.4, moderate                274 
in 0.4-0.59, good in 0.6 – 0.79, and excellent in 0.89 – 1.0.       275 
 276 
Table 4.  277 
Comparison of the serological and  proviral status in hospitalized patients with ATL treated 278 
by either BMT or intensive chemotherapy.  279 
The cut off value of CLEIA is 1.0. (+): positive, but no number data.  280 
NT means nottested.1.0< means over 1.0 and below 1.2. 281 
 282 
  283 
 284 
A No.60 No.62 
No.60 














Figure 1 .  
No.60 No.62 No.100 
No.100 





















Table 1 .   
  PA CLEIA CLIA WB（WHO) 
Positive 99(94.3%) 98(93.3%) 97(92.4%) 86(81.9%) 
Indeterminate 0 0 0 15(14.3%) 
Negative 6(5.7%) 7(6.7%) 8(7.6%) 4(3.89%) 
Table 2.  
Case No. CLEIA CLIA PA WB  results                                                                                                       
band pattern molecular test 
env gag 
qPCR nPCR 
gp46 p53 p24 P19 
group A 
21 0.5 0.12 ＋ Indeterminate - ＋ ＋ ＋     
60 25.9 44.15 ＋ Indeterminate - ＋ ＋ ＋ 0.01%(+) (+) 
50 14.3 90.7 ＋ Indeterminate - ＋ ＋ ＋     
35 2.4 3.98 ＋ Indeterminate - ＋ ＋ ＋     
100 8.3 53.12 ＋ Indeterminate - ＋ ＋ ＋ 0.02%(+) (+) 
3 34 90.4 ＋ Indeterminate - ＋ ＋ ＋     
group B 
92 0.2 0.14 - Indeterminate - - ＋ -     
64 0.1 0.27 - Indeterminate - - ＋ -     
18 6.3 53.44 ＋ Indeterminate - - ＋ -     
58 0.1 0.13 - Indeterminate - - - ＋     
32 1.7 1.54 ＋ Indeterminate - - - ＋     
65 1.2 7.55 - Indeterminate - - - ＋     
62 14.7 40.17 ＋ Indeterminate - - - ＋ (+) (+) 
15 5.5 4.95 ＋ Indeterminate - ＋ - ＋     
33 8.7 24.45 ＋ Indeterminate - ＋ - ＋     
group C 
29 3.3 0.1 - - - - - -     
67 0.1 0.12 - - - - - -     
94 0.2 0.12 - - - - - -     
40 0.1 0.49 ＋ - - - - -     
Table 3 .  
proportion of 
kappa-statistics 
  agreement 
PA - WB 0.88 0.488 
CLEIA - WB 0.87 0.428 
CLIA - WB 0.89 0.542 
PA -  CLEIA 0.96 0.693 
PA - CLIA 0.96 0.846 
CLEIA -  CLIA 0.99 0.928 






PVL (%) nestedPCR amplified site of standard curve CLEIA   No 
group Ⅰ qPCR (+) 
  
1 0.50% NT border 1.3 
2 0.50% NT out of linear R 14.9 
3 0.50% NT out of linear R 10.5 
4 0.50% NT out of linear R 2.4 
5 0.40% NT out of linear R 38.1 
6 0.40% NT out of linear R 38.1 
7 0.40% NT out of linear R 1.0< 
8 0.40% NT out of linear R 1.0< 
9 0.40% NT out of linear R 2.4 
10 0.40% NT out of linear R 1.0< 
11 0.40% NT out of linear R 1.0< 
12 0.40% NT out of linear R 2.4 
13 0.40% NT out of linear R 39.5 




15 0.00% nPCR(+) no amplicon curve 1.2 
16 0.00% nPCR(+) no amplicon curve 5.4 
17 0.00% nPCR(+) no amplicon curve 6.3 
18 0.00% nPCR(+) no amplicon curve 9.8 
19 0.00% nPCR(+) no amplicon curve 18.9 
20 0.00% nPCR(+) no amplicon curve 0.1 




22 0.00% nPCR(-) no amplicon curve 0.5 
23 0.00% nPCR(-) no amplicon curve 0.8 
24 0.00% nPCR(-) no amplicon curve 0.8 
25 0.00% nPCR(-) no amplicon curve 0.2 
